- Home
- CLNN vs AGEN Comparison
CLNN vs AGEN Comparison
Compare CLNN & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLNN | AGEN |
|---|---|---|
| Founded | 2012 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.6M | 126.8M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | CLNN | AGEN |
|---|---|---|
| Price | $5.72 | $3.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $32.67 | $14.50 |
| AVG Volume (30 Days) | 290.7K | ★ 493.3K |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $214,000.00 | ★ $106,829,000.00 |
| Revenue This Year | N/A | $60.49 |
| Revenue Next Year | $87.58 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.28 | $1.38 |
| 52 Week High | $13.50 | $7.34 |
Technical Indicators
Market Signals| Indicator | CLNN | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 32.08 | 39.98 |
| Support Level | $8.90 | $4.05 |
| Resistance Level | $9.92 | $4.64 |
| Average True Range (ATR) | 1.03 | 0.22 |
| MACD | -0.40 | -0.04 |
| Stochastic Oscillator | 2.12 | 1.39 |
Price Performance
Historical ComparisonAbout CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).